Navigation Links
Innerscope Research(R) Receives Three Great Minds Innovation Awards from the Advertising Research Foundation
Date:4/20/2009

CEO Dr. Carl Marci Wins Gold Innovation Award; Senior Scientist Dr. Caleb Siefert Wins Silver Innovation Award; President Brian Levine Receives Certificate of Recognition

BOSTON, April 6 /PRNewswire/ -- Innerscope Research(R), a revolutionary biometric media research firm specializing in Emotional Response Measurement, has received three Great Minds Innovation Awards from the Advertising Research Foundation.

The Innovation Awards, which were presented last week in New York during Re:think 2009: The ARF Annual Convention + Expo, are given annually to people or teams who develop the most innovative research ideas.

Carl Marci, Harvard M.D. and CEO of Innerscope received the Gold Innovation Award for a collaborative study with Olson Zaltman Associates (OZA). To help a major food manufacturer optimize creative executions for packaging and advertising (print and TV), Dr. Marci combined biometrics and the patent-pending eye tracking Innerscope Impact Map(TM).

"It's an honor to be recognized by the Advertising Research Foundation, which stands at the forefront of accepting and promoting new research methodologies, for our ability to take the long awaited promise of neuromarketing and deliver concrete results quickly for clients," said Dr. Marci, who also received a certificate of recognition from the Great Minds Rising Star Awards.

Dr. Siefert, Senior Scientist at Innerscope Research and instructor at Harvard Medical School, received a Silver Innovation Award for research that helped a major cable television network maximize the impact of ads in shows through product placement.

Brian Levine, MIT scientist, president and cofounder of Innerscope Research, received a certificate of recognition for a study conducted on behalf of a major television network that evaluated how audi
'/>"/>

SOURCE Innerscope Research
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology news :

1. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
2. Innerscope Research(R) Uses Same-Day Results From Biometric Study to Identify Key Themes, Styles Behind Effective, Engaging Speaker Presentations
3. Innerscope Research(R) Appoints Digital Leader, Andre Marquis, as Senior Vice President of Sales and Marketing
4. Innerscope Research(R) Receives Three Great Minds Innovation Awards from the Advertising Research Foundation
5. Rutgers Genetics receives $7.8 million for autism research
6. Herr receives Heinz Award for Technology, the Economy and Employment
7. UCI receives $5M from Edwards Lifesciences
8. Yu receives research funding from the Wallace H. Coulter Foundation
9. UGA Odum School of Ecology professor receives grant to study West Nile Virus in NYC
10. UC Riverside biologist receives prestigious MacArthur Fellowship
11. UC Irvine receives $2.18M to explore nano advancements in DNA sequencing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
Breaking Biology News(10 mins):How nutrition affects healthy aging 2New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 1Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 2Hospira Receives Favorable Court Decision on Eloxatin 28R 29 12701 3Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 1Traumatic brain injury caused by exposure to explosive blast presents critical challenge 49434 2Antibiotics take toll on beneficial microbes in gut 8909 1Antibiotics take toll on beneficial microbes in gut 8909 2Antibiotics take toll on beneficial microbes in gut 8909 3
... PLAIN, N.Y., JULY 27, 2008 In a new March of Dim...tentially deadly disorder that affects about 5 per...s in mice that may have important implications for....D., Ph.D., and Rodney E. Kellems, Ph.D., Departme...n M. Ramin, M.D., Department of Obstetrics, Gyneco...
...MINGHAM, Ala. The life expectancy for patients wi...d by more than 13 years since the late 1990s thank...ding to researchers at the University of Alabama a...Vancouver, British Columbia. , Improved survival ... among 43,355 HIV-positive study participants in E...
...GO (July 25, 2008) New research published in the ... of Surgeons shows elevated plasma DNA is a relia...dy also suggests that plasma DNA levels rise befor...jority of patients. , Esophageal cancer, one of...usually diagnosed at a late stage. An accurate mar...
Other Biology News:New research on pre-eclampsia in mice may have important implications for humans 2Anti-HIV therapy boosts life expectancy more than 13 years 2Plasma DNA level is a reliable marker of recurrent esophageal cancer, study finds 2
(Date:12/4/2009)IRVINE, Calif., Dec. 4 BlueFire Ethanol Fuels, Inc. (OTC Bulletin Board: BFRE), a company focused on changing the world,s transportation fuel paradigm through the production of ethanol from non-food
(Date:12/3/2009)PHILADELPHIA, Dec. 3 Shire plc (LSE: SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical company, today announced a voluntary recall of five lots and voluntary market withdrawal of one lot
(Date:12/2/2009)COLUMBIA, Md., Dec. 2 Martek Biosciences Corporation (Nasdaq: MATK ) announced today that it intends to release the results of its fourth quarter and fiscal year 2009 on December 16, 2009, at approx
(Date:12/2/2009)NEW YORK, Dec. 2 Nearly 600 medical research executives, scientists, policy makers, and funders today convened to explore novel development approaches and innovative funding strategies at the inaugur
Breaking Biology Technology:BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 2BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 3BlueFire Named One of Top 20 Bioenergy Companies for Second Consecutive Year 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 2Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 3Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 4Non-safety-related voluntary recall of a limited portion of Daytrana(R) (methylphenidate transdermal system) patches announced 5Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2
...ewswire-FirstCall/ - SemBioSys Genetics Inc.,(TSX:...io of therapeutic,proteins for metabolic and cardi...gible to proceed with its planned Phase I/II human... the 30-day review period of its,Investigational N...bmitted,the application in July to the U.S. Food a...
...ins momentum with launch of a Phase ...LE, Md., Sept. 16 Novavax, Inc.,(Nasdaq: NVAX ) ...in a Phase,II clinical trial of its virus-like par...Phase IIa randomized, placebo controlled clinical ...of different doses of its seasonal,influenza VLP v...
...l/ - MIGENIX Inc. (the,"Company" or "MIGENIX") (TS... drugs for infectious diseases, reports financial ...nd provides a corporate update on its programs,and...AMS, Omiganan 1% gel (Omigard(TM)/CPI-226/MX-226;...related infections): Cadence Pharmaceuticals, Inc....
Other Biology Technology:SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 2SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 4Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 2MIGENIX Reports First Quarter Fiscal 2009 Financial Results 3MIGENIX Reports First Quarter Fiscal 2009 Financial Results 4MIGENIX Reports First Quarter Fiscal 2009 Financial Results 5MIGENIX Reports First Quarter Fiscal 2009 Financial Results 6MIGENIX Reports First Quarter Fiscal 2009 Financial Results 7MIGENIX Reports First Quarter Fiscal 2009 Financial Results 8MIGENIX Reports First Quarter Fiscal 2009 Financial Results 9MIGENIX Reports First Quarter Fiscal 2009 Financial Results 10MIGENIX Reports First Quarter Fiscal 2009 Financial Results 11
Chicken Anti-HOXC11 Polyclonal Antibody, Unconjugated from ProSci, Inc
Rabbit Anti-Raf1 Polyclonal Antibody, Unconjugated from Abcam
Sheep Anti-Human hCG beta core fragment Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-SIT Monoclonal Antibody, Unconjugated, Clone SIT-01 from Abcam
Biology Products: